Delayed onset panuveitis following intravitreal aflibercept injection

BMJ Case Reports

Volumn , Issue , 2014, Pages

  Glading, Jodi A ^a   Lake, Stewart R ^a,b   Craig, Jamie E ^a,b   Supramaniam, Devaraj ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; BRINZOLAMIDE; CEFAZOLIN; CHLORAMPHENICOL; FLUOROMETHOLONE; LATANOPROST; PREDNEFRIN; RANIBIZUMAB; TIMOLOL; VANCOMYCIN;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; CASE REPORT; CATARACT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXUDATIVE MACULAR DEGENERATION; EYE IRRITATION; EYE PAIN; FEMALE; HUMAN; HYPOPYON; INTRAOCULAR PRESSURE; LENS IMPLANT; LENSECTOMY; MALE; OPEN ANGLE GLAUCOMA; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PSEUDOEXFOLIATION; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; UVEITIS; VERY ELDERLY; VISUAL ACUITY; VITRECTOMY; VITRITIS;

EID: 84902603282     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2013-202515     Document Type: Article

References (15)

1. Kiss C, Michels S, Prager F, et al. Evaluation of anterior chamber inflammation activity in eyes treated with intravitreal bevacizumab. Retina 2006;26:877-81. (Pubitemid 44547439)
2. Ladas ID, Karagiannis DA, Rouvas AA, et al. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina 2009;29:313-18.
3. Georgopoulos M, Polak K, Prager F, et al. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol 2009;93:457-62.
4. Chong DY, Anand R, Williams PD, et al. Characterization of sterile intraocular inflammatory responses after intravitreal bevacizumab injection. Retina 2010;30:1432-40.
5. Rosenfeld PJ, Brown DM, Heler JS, et al.; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31. (Pubitemid 44511557)
6. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus vertepor fin for neovascular age related macular degeneration. N Engl J Med 2006;355:1432-44. (Pubitemid 44511558)
7. London NJS, Garg SJ, Moorthy RS, et al. Drug-induced uveitis. J Ophthal Inflamm Infect 2013;3:43.
8. Wickremasinghe SS, Michalova K, Gihortra J, et al. Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 2008;115:1911-15.e1
9. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;3:1897-908.
10. Fauser S, Schroeder S, Caramoy A, et al. Intraocular infl ammation after intravitreal ranibizumab injections. Acta Ophthalmol 2011;89:e98-9.
11. Damasceno N, Horowitz S, Damasceno E. Anterior uveitis after treatment of age-related macular degeneration with ranibizumab and bevacizumab: uncommon complication. Clin Ophthalmol 2012;6:1201-5.
12. Hahn P, Kim JE, Stinnett S, et al. Aflibercept-related sterile inflammation. Ophthalmology 2013;120:1100-1.
13. Blumberg S, Bienfang D, Kantrowitz FG. A possible association between influenza vaccination and small-vessel vasculitis. Arch Intern Med 1980;3:847-8. (Pubitemid 10120848)
14. Thurairajan G, Hope-Ross MW, Situnayake RD, et al. Polyarthropathy, orbital myositis and posterior scleritis: an unusual adverse reaction to influenza vaccine. Br J Rheumatol 1997;3:120-3.
15. Blanche P, Decrette C, Sicard D. Development of uveitis following vaccination for influenza. Clin Infect Dis 1994;19:979. (Pubitemid 24368853)